SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

$FEFE is trending as the community doubles down on the "three frogs" narrative, positioning the token as the official Matt Furie-created successor to the Pepe frog lineage. Investors are actively debating its potential as an undervalued micro-cap beta play, with the community emphasizing its resilience through market volatility and consistent organic growth.

The Render Network is a leading decentralized GPU compute platform for applications ranging from 3D rendering to machine learning and generative AI.  The network connects node operators looking to monetize their idle GPU compute power with artists and developers looking to scale intensive 3D rendering work and machine learning applications in the cloud. Through a decentralized peer-to-peer network, the Render Network achieves unprecedented levels of scale, speed, and economic efficiency. Facilitated by the Render Network Foundation, the ecosystem empowers artists and developers to build services and applications for the emerging digital economy.

Render Token (SOL)

Render Token is attracting significant attention as investors position themselves for the decentralized AI compute and DePIN sectors, with many citing its utility and potential for long-term growth as key drivers. While some in the community remain skeptical, bullish sentiment is fueled by active discussions around the network's efficiency and its critical role in powering the expanding AI application ecosystem.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is gaining traction as a critical real-world asset (RWA) infrastructure play, driven by its institutional-grade data feeds and a unique revenue model that includes a monthly token buyback program. Community members are actively highlighting its utility, government-level partnerships, and perceived growth potential as a foundational layer for the expanding decentralized finance ecosystem.

Dogelon Mars

Dogelon Mars is currently generating intense community debate as holders weigh the potential for a meme coin resurgence against long-standing frustration over its lack of utility and historical underperformance. While some investors see the low valuation as a speculative opportunity to accumulate during market volatility, others are vocally warning of a 'pump and dump' cycle, reflecting a sharp divide between long-term 'diamond hands' and those urging an exit.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility as investors speculate on the upcoming Goliath mainnet launch and look for signs of a breakout from its recent consolidation range. Community sentiment is deeply divided, with many traders debating whether the current price action signals a genuine accumulation phase or another repeat of previous pump-and-dump cycles.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending following the announcement that it has selected Siemens Energy to supply steam turbine generator sets for a major 1 GW data center power project, which investors view as a pivotal step toward finalizing a transformative contract with Applied Digital. Community sentiment is highly bullish as market participants look past historical volatility, focusing instead on the company's emerging role in providing critical, non-grid-connected power solutions for AI infrastructure.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is seeing heightened market interest and volatility as investors speculate on its pivotal role in the future of AI-driven identity verification and human authentication. The community is actively debating the project's potential as a long-term utility asset versus privacy concerns, fueled by ongoing treasury accumulation news and high-profile connections to Sam Altman's broader AI ecosystem.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing high community engagement driven by speculation that its rugged edge computing hardware is integrated into major defense platforms, including potential involvement in recent multi-billion dollar government contracts. Investors are closely monitoring the stock as a key pure-play in the edge AI and defense sectors, anticipating upcoming earnings and potential follow-on awards to catalyze further growth.

MGM Resorts International is a holding company, which engages in the ownership and operations of casino resorts. The firm's casino resorts offer gaming, hotel, convention, dining, entertainment, retail, and other resort amenities. It operates through the following business segments: Las Vegas Strip Resorts, Regional Operations, MGM China, and MGM Digital. The Las Vegas Strip Resorts segment operates the following casino resorts: Bellagio, MGM Grand Las Vegas, Mandalay Bay, The Mirage, Luxor, New York-New, Excalibur, Park MGM, and Circus Las Vegas. The Regional Operations segment consists of the following casino resorts: MGM Grand Detroit in Detroit, Michigan, Beau Rivage in Biloxi, Mississippi, Gold Strike Tunica in Tunica, Mississippi, Borgata in Atlantic City, New Jersey, MGM National Harbor in Prince George’s County, Maryland, and MGM Springfield in Springfield, Massachusetts. The MGM China segment includes MGM Macau and MGM Cotai. The MGM Digital segment focuses on the online gaming portfolio, which consists primarily of Leo Vegas, which is headquartered in Sweden and Malta. The company was founded by Kerkor Kerkorian on January 29, 1986 and is headquartered in Las Vegas, NV.

MGM Resorts International

MGM Resorts is capturing market attention as investors weigh its robust recent earnings and positive forward guidance against broader sector concerns regarding shifting discretionary spending and potential regulatory headwinds. The community is actively debating the company's valuation relative to its digital growth initiatives in the iGaming space and its long-term expansion plans in international markets like Japan.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing a surge in community engagement and institutional interest, driven by its pivotal role as infrastructure for real-world asset (RWA) tokenization and upcoming regulatory catalysts. Investors are actively debating the asset's long-term utility against its current price action, with many highlighting recent whale accumulation and increased usage of its cross-chain interoperability protocols as potential drivers for a breakout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

Eastman Kodak’s shares rallied nearly 12% in extended hours of trading on Thursday after it reported strong growth in its fourth-quarter revenue.&nbsp;Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%. The rise in revenue was driven by strong performance in Advanced Materials &amp; Chemicals (AM&amp;C) and Print segments.&nbsp;“Kodak ended 2025 with a strong fourth quarter, which has created a foundation for growth in 2026,” said Jim Continenza, Kodak’s Executive Chairman and CEO. “We continue to execute the long-term plan we began in 2019, which focuses on de-levering the company while continuing to invest in our infrastructure and new product innovation”.&nbsp;Kodak ended the year with a cash balance of $337 million, an increase of $136 million from December 31, 2024. The increase was primarily due to the net impact of the Kodak Retirement Income Plan (KRIP) termination and reversion of assets to the company of $153 million.The company reported GAAP net loss of $108 million in Q4 2025, compared with net income of $26 million for Q4 2024. The decline in net income was primarily due to the non-recurring impact of the Kodak Retirement Income Plan ("KRIP") termination and excise tax paid on the reversion of assets to the company.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around KODK stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;One user on Stocktwits called the share rise ‘better than expected’.<stembedurl>https://stocktwits.com/PharmGal/message/647406000</stembedurl>A bullish user said they are optimistic for Kodak in 2026.&nbsp;<stembedurl>https://stocktwits.com/NikkyBenz13/message/647405165</stembedurl>Another bullish user opined that continued growth in Kodak’s Advanced Materials &amp; Chemicals is especially encouraging and could open doors to new markets.&nbsp;<stembedurl>https://stocktwits.com/Judykay/message/647399877</stembedurl>Shares in the company are down 9.4% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

In this photo illustration, the Eastman Kodak Company logo is seen displayed on a smartphone screen.

Eastman Kodak Stock Rallies After-Hours As Q4 Revenue Jumps On Strong Segment Performance

Kodak reported consolidated revenues of $290 million in the fourth quarter of 2025, compared with $266 million in the year-ago period, an increase of $24 million or 9%.

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

<ul class="summary-bullets"><li>The company swung to profit in Q4 and reported earnings per share of $0.05 versus year-ago loss per share of $0.22.</li><li>Adjusted operating expenses for the fourth quarter of 2025 were $6.5 million compared to $11.9 million for the fourth quarter of 2024.</li><li>On Stocktwits, retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;</li></ul>DigiMarc (DMRC) shares rallied 7% during extended hours of trading after it reported a&nbsp;higher-than-expected&nbsp;fourth-quarter (Q4) revenue on Wednesday.&nbsp;DMRC’s total revenue for Q4 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024. Analysts on average expected $8.2 million in revenue, as per data from&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>.&nbsp;<h2 class="st-heading-2">Q4 Snapshot</h2>DigiMarc’s subscription revenue for Q4 2025 came at $5.3 million compared to $5.0 million for the fourth quarter of 2024. The increase reflects $1.4 million of patent license fees earned during the quarter and higher subscription revenue from new and existing commercial contracts, partially offset by a $1.4 million decrease relating to the expiration of two previously disclosed commercial contracts in 2025,&nbsp;the company said.The company's adjusted net income for Q4 2025 was $1.0 million or $0.05 per diluted share compared to adjusted net loss of $4.6 million or $0.22 per diluted share for the fourth quarter of 2024.“Digimarc is capitalizing on the convergence of key trends driving increased demand for our solutions, positioning ourselves to benefit from - not be the casualty of - the relentless advance of AI," said Riley McCormack, Digimarc CEO. "In Q4 2025, we achieved both positive non-GAAP net income and positive free cash flow. Looking ahead to 2026, we expect to generate significant ARR growth."<h2 class="st-heading-2">Expenses Come Down</h2>Operating expenses for the quarter were $10.0 million, compared to $14.4 million for Q4 2024.&nbsp;The decrease was led by lower cash compensation costs of $4.4 million, largely due to lower headcount, and lower professional services costs of $0.6 million, partially offset by higher stock compensation costs of $0.7 million.&nbsp;Adjusted operating expenses for the quarter were $6.5 million compared to $11.9 million for Q4 2024.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around DMRC&nbsp;stock trended in ‘extremely bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company have fallen 9.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Stocktwits, retail sentiment around DMRC stock trended in ‘extremely bullish’ territory amid ‘high’ message volume. 

DigiMarc Stock Rallies After Hours On Q4 Revenue Beat

DMRC’s total revenue for the fourth quarter of 2025 was $8.9 million compared to $8.7 million for the fourth quarter of 2024.

<ul class="summary-bullets"><li>The company said it expects Bumble App Revenue of $171 million to $174 million for Q126.</li><li>In Q4, total revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter.</li></ul>Shares of Bumble rallied nearly 25% during Wednesday’s extended hours of trading as upbeat outlook for first-quarter revenue cushioned worries from weakness in fourth-quarter earnings.&nbsp;&nbsp;The company said it expects total&nbsp;revenue&nbsp;for Q1 2026 to be in the range of $209 million to $213 million, which includes Bumble App Revenue of $171 million to $174 million. Analysts on average&nbsp;estimate revenue of $210 million.&nbsp;BMBL expects adjusted core profit in the range of $76 million to $80 million for the quarter.<h2 class="st-heading-2">Weak Q4</h2>Total Revenue decreased 14.3% to $224.2 million, compared to $261.6 million from the year-ago quarter. Bumble App revenue also fell 14.8% to $181.0 million, compared to $212.4 million.Bumble’s Total Paying Users slumped 20.5% to 3.3 million, compared to 4.2 million.The company said&nbsp;its fourth quarter net loss was $611.1 million, compared to net earnings of $9.3 million from the year-ago quarter.&nbsp;<h2 class="st-heading-2">FY 2025</h2>In FY2025, Bumble’s total revenue decreased 9.9% to $965.7 million, compared to $1.07 billion. Total Paying Users decreased 11.5% to 3.7 million, compared to 4.1 million.&nbsp;“In 2025, we made the deliberate choice to return Bumble to its women-first foundation, raising the bar on trust and authenticity while addressing pain points our members experience with online dating,” said Whitney Wolfe Herd, Founder &amp; CEO of Bumble Inc.“With the heavy lift of our quality reset behind us, we are accelerating product innovation and prioritizing member experience enhancements. We are building from a stronger base and positioning Bumble for its next chapter of product-led growth,” Herd said.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around BMBL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in BMBL have fallen 2.4% year-to-date.&nbsp;

The exterior of Bumble Headquarters on July 15, 2024 in Austin, Texas. 

Bumble Stock Is Rallying Today After Hours – What Is Causing The Bull Run?

The company said it expects total revenue for Q1 2026 to be in the range of $209 million to $213 million. Analysts on average estimate revenue of $210 million. 

<ul class="summary-bullets"><li>The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted.</li><li>It added that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.&nbsp;</li><li>Sarepta Therapeutics’s FDA-approved DMD gene therapy Elevidys came under scrutiny last year over concerns of acute liver failure and associated patient deaths.</li></ul>REGENXBIO Inc. (RGNX) on Wednesday announced positive interim data from the company’s early-to-mid stage trial of its gene therapy for Duchenne muscular dystrophy.The investigational gene therapy RGX-202 demonstrated evidence of positively changing disease trajectory for the disease in a few patients enrolled in the trial. It further exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said.The only drug-related adverse events observed are typically anticipated with gene therapy administration, the company noted, while adding that a proactive, short-course immune modulation regimen in combination with a differentiated construct and industry-leading product purity levels may contribute to a favorable safety profile for RGX-202.Sarepta Therapeutics’s (SRPT) FDA-approved DMD gene therapy, Elevidys, came under scrutiny last year over concerns of acute liver failure and associated patient deaths. Duchenne muscular dystrophy (DMD) is a severe, progressive genetic muscle disease affecting mostly boys.<h2 class="st-heading-2">Application Timeline</h2>REGENXBIO now expects to share topline data from the trial in early second quarter and request a meeting with the FDA in mid-2026, ahead of filing an application seeking approval for the gene therapy.In the meantime, the company will continue to enroll participants for its confirmatory trial, which is expected to have about 30 participants. The company said on Wednesday that it expects to have the majority of the trial enrolled at the time of the application submission.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around RGNX stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘extremely low’ levels.<a href="https://stocktwits.com/symbol/RGNX">RGNX stock</a> has gained nearly 54% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/joby-aviation-makes-first-steps-towards-faa-certification-of-aircraft/cZdrOkARIBb">Joby Aviation Makes First Steps Towards FAA Certification Of Aircraft</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study 

The investigational gene therapy RGX-202 exhibited a favorable safety profile with no serious adverse events and no evidence of liver injury, the company said. 

<ul class="summary-bullets"><li>The onshore pipelines of SOC have been shut down for a decade since the 2015 Refugio Beach oil spill.</li><li>The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products.</li><li>Sable in December had said that it received an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.</li></ul>U.S. President Donald Trump is reportedly set to summon authorities under the Defense Production Act to preempt state laws and ease permitting for Sable Offshore Corp. (SOC)&nbsp; to restart significant production from a cluster of offshore platforms in California.According to a Bloomberg News report, a White House official said that any policy announcement would come directly from the president.&nbsp;The efforts come at a time when the U.S.-Israel war with Iran has disrupted global supply of oil and other key energy products due to the blockade of Strait of Hormuz by Iran.&nbsp;The onshore pipelines have been shut down for a decade since the 2015 Refugio Beach oil spill, when a corroded segment of one pipeline ruptured and released hundreds of thousands of gallons of oil near Santa Barbara.Shares of&nbsp;SOC jumped 18% at the time of writing.&nbsp;&nbsp;<h2 class="st-heading-2">SOC’s Feud</h2>California Attorney General Rob Bonta earlier in the month filed a lawsuit against the Trump Administration, challenging the Pipeline and Hazardous Materials Safety Administration’s (PHMSA) orders that “illegally assert” exclusive jurisdiction over two California onshore oil pipelines of Sable offshore which are known as the Las Flores Pipelines or lines CA-324 and CA-325, and allow them to restart operations.Sable in December had said that it received a receipt of an emergency special permit from PHMSA for Santa Ynez Pipeline System Segments.<h2 class="st-heading-2">IEA Announcement</h2>Earlier in the day, the International Energy Agency announced that all its 32 member countries had unanimously agreed to release 400 million barrels of oil from their emergency reserves to help address disruptions in oil markets caused by the war in the Middle East.Retail sentiment around SOC trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in SOC have jumped 59.4% so far in 2026.For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

A crane ship helps other vessels searching for oil and natural gas near the oil platform offshore the Red Sea in Ras Behar region, Egypt.

Sable Offshore To Reportedly Get Trump Support Via Emergency Law To Restart Production

A White House official said that any policy announcement would come directly from the president, as per a Bloomberg News report. 

<ul class="summary-bullets"><li>Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.&nbsp;</li><li>Despite the strong results, Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.&nbsp;</li><li>Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.</li></ul>Domo Inc. (DOMO), a cloud software company that leverages artificial intelligence to provide real-time business data to improve executive decision-making, posted fourth-quarter (Q4) results on Tuesday that beat analysts’ expectations.Despite the strong results, Wall Street analysts slashed price targets on the company. Lake Street lowered its price target on Domo to $7 from $13 and kept a ‘Hold’ rating on the shares, as per TheFly.DA Davidson and Cantor Fitzgerald also lowered their price targets on the Utah-based company.<h2 class="st-heading-2">Street Rationale</h2>Lake Street analyst Eric Martinuzzi said the lowered price target reflected a fair takeout price for the growth-challenged SaaS business after the company said in its earnings release that it expects revenue to be flat in FY27 with modest growth in its earnings per share.DA Davidson analyst Lucky Schreiner lowered the price target on Domo to $6 from $10 and kept a ‘Neutral’ rating on the shares. While the firm noted Domo’s strong Q4 results, it said that it is waiting to see more upside to revenue growth prospects before becoming more constructive.Cantor Fitzgerald cut the price target on the company to $8 from $13 and maintained an ‘Overweight’ rating on the shares, citing lower overall software multiples.Based on data from Koyfin, Wall Street has a 12-month average target of $9.58 on Domo shares, representing an upside potential of about 90% compared to the current price levels of $5.04.<h2 class="st-heading-2">Domo Q4 Snapshot</h2>The SaaS company posted a marginal 1% growth in Q4 revenue, coming in at $79.6 million, higher than consensus estimates of $79.03 million. Domo also reported EPS of $0.03, while the Street expected the company to post a loss of $0.03 per share.However, the company refrained from providing specific forward-looking guidance, citing ongoing evaluation of strategic alternatives. The company’s CFO, Tod Crane, however clarified that Domo expects GAAP revenue to remain relatively flat for fiscal year 2027, and modest improvement in non-GAAP EPS and positive adjusted free cash flow.<h2 class="st-heading-2">Retail Sentiment</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/DOMO">DOMO shares</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volumes climbed to ‘extremely high’ levels.Shares of DOMO climbed after the results, and continued to increase on Wednesday. In the past year, DOMO stock has declined more than 37%.Meanwhile, <a href="https://stocktwits.com/symbol/IWM">iShares Russell 2000 ETF</a> (IWM) has climbed by over 25% in the past year, while the <a href="https://stocktwits.com/symbol/VTI">Vanguard Total Stock Market Index Fund ETF</a> (VTI) has gained more than 21%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a US flag is displayed on a smartphone and stock market prices in the background. (Photo Illustration by Romain Doucelin/SOPA Images/LightRocket via Getty Images)

Domo Posted A Double Beat On Q4 Results — So Why Is The Street Slashing Targets?

The cloud software company posted Q4 results on Tuesday, with revenue coming in at $79.6 million, higher than consensus estimates of $79.03 million.

<ul class="summary-bullets"><li>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.</li><li>Aldeyra resubmitted its application seeking approval for the drug in July after previous rejections.&nbsp;</li><li>While the agency was initially expected to rule on the application by December, it later extended it until March 16.</li></ul>Shares of Aldeyra Therapeutics (ALDX) garnered retail attention on Stocktwits on Tuesday as the company approaches the date for potential approval of its dry eye treatment Reproxalap.The U.S. Food and Drug Administration (FDA) is slated to rule on the company’s application seeking approval for Reproxalap by March 16. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ALDX stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.Users are sharply divided between hopes for approval following a draft label and a recent procedural extension, and concerns over prior rejections.A Stocktwits user expressed optimism for an imminent approval, saying that the FDA has never rejected a drug so many times.<stembedurl>https://www.stocktwits.com/Dragan7/message/647163937</stembedurl>Another expressed hopes for more information as early as Thursday.<stembedurl>https://www.stocktwits.com/UpAndDownUpAndDown/message/647145449</stembedurl><a href="https://stocktwits.com/symbol/ALDX">ALDX stock</a> has dropped 24% over the past 12 months.<h2 class="st-heading-2">Approval Updates</h2>Aldeyra resubmitted its application seeking approval for Reproxalap in July after <a href="https://stocktwits.com/news-articles/markets/equity/aldeyra-therapeutics-stock-slumps-after-fda-letter/chf7PxrRbe1">previous rejections</a>. &nbsp;While the agency was initially expected to rule on the application by December, it later extended it until March 16 to review the additional submissions made by the company as proof of efficacy of its therapy. The company then said that the FDA made no requests or flagged any specific issues with its application review in a meeting in December.Aldeyra first submitted an application to the FDA for Reproxalap in November 2022, but the agency asked for more trials. The company subsequently resubmitted its application in October 2024 but it was rejected in April with the FDA saying the company’s trials failed to demonstrate its efficacy.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/qure-stock-edges-up-after-hours-as-analyst-flags-reduced-regulatory-uncertainty-after-prasad-fda-exit/cZdY5SrRI7s">QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Aldeyra Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ALDX Stock Garners Retail Interest: Investors Debate Dry Eye Treatment Approval Amid Long Wait

The U.S. Food and Drug Administration is slated to rule on the company’s application seeking approval for Reproxalap by March 16.  

<ul class="summary-bullets"><li>GRPN’s net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;</li><li>The company’s active customers were 16.2 million as of December 31, 2025.</li><li>International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year.&nbsp;</li></ul>Shares of Groupon fell 11% during extended hours of trading on Tuesday after it posted a fourth quarter revenue that fell short of Wall Street expectations.&nbsp;The company said its revenue was $132.7 million in the fourth quarter 2025, up 2% compared with the prior year period. It was below analyst expectations of $136.7 million, as per data from Fiscal.ai.&nbsp;Its net income from continuing operations was $8.1 million in the fourth quarter 2025 compared with net loss from continuing operations of $50.1 million in the prior year period.&nbsp;"Our 2025 results represent a landmark achievement in Groupon’s multi-year transformation, as we returned to growth in both billings and revenue for the first time in a decade," said Dusan Senkypl, CEO of Groupon.The company’s active Customers were 16.2 million as of December 31, 2025.<h2 class="st-heading-2">Segment Performance</h2>GRPN’s North America revenue was $98.7 million in the fourth quarter 2025, up 2% compared with the prior year period. Region’s gross billings were $323.8 million in the fourth quarter 2025, up 6% year-over-year.&nbsp;International revenue was $34.0 million in the fourth quarter 2025, up 1% compared with the prior year period. However, International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. Excluding Giftcloud and Italy, International Local billings increased 16% in the quarter.&nbsp;International unit sales were 3.5 million in the fourth quarter 2025, up 21% sequentially and down 5% compared with the prior year period.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment around GRPN trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen 43.4% year-to-date.&nbsp;

Groupon's International gross billings were $122.7 million in the fourth quarter 2025, down 1% year-over-year. 

Groupon Stock Fell 11% After Hours – Here’s Why

The company said its revenue was $132.7 million in the fourth quarter 2025, below analyst expectations of $136.7 million, as per data from Fiscal.ai. 

iShares Trust - iShares Russell 2000 ETF

Up 5%

Down 5%

Show me the results

Which direction is the next 5% move for the S&amp;P 500?

Stocktwits

Which direction is the next 5% move for the S&P 500?

Stocktwits Polls

iShares Russell 2000 ETF

Geopolitical tensions in the Middle East and concerns over the Strait of Hormuz are fueling oil price surges and broader market uncertainty.

IWM continues to show significant weakness and deeper declines, raising concerns about small-cap performance in the current market environment.

Recent economic releases, including downward GDP revisions and firm PCE inflation, signal a cooling economy and potential Fed policy pressure.

Significant put buying activity and an increased put-to-call ratio indicate growing bearish sentiment and hedging around IWM options.

Multiple technical indicators, including RSI, suggest extreme oversold conditions for IWM, prompting discussion of potential demand areas or further downside.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWM News

IWMiShares Russell 2000 ETF